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A
 
BSTRACT
 
Background
 
We conducted a double-blind, ran-
domized trial of three dilutions of vaccinia virus vac-
cine in previously unimmunized adults in order to
assess the clinical success rates, humoral responses,
and virus-specific activity of cytotoxic T cells and in-
terferon-
 
g
 
–producing T cells.
 
Methods
 
Sixty healthy adults were inoculated in-
tradermally by bifurcated needle with undiluted vac-
cine (dose, 10
 
7.8
 
 plaque-forming units [pfu] per milli-
liter), a 1:10 dilution (dose, 10
 
6.5
 
 pfu per milliliter), or
a 1:100 dilution (dose, 10
 
5.0
 
 pfu per milliliter); there were
20 subjects in each group. The subjects were moni-
tored with respect to vesicle formation (an indicator
of successful vaccination), the viral titer at the time of
peak lesion formation, antiviral antibodies, and cellu-
lar immune responses.
 
Results
 
A vaccinia vesicle developed in 19 of the
20 subjects who received undiluted vaccine (95 per-
cent), 14 of the 20 who received the 1:10 dilution (70
percent), and 3 of the 20 who received the 1:100 di-
lution (15 percent). One month after vaccination, 34
of 36 subjects with vesicles had antibody responses,
as compared with only 1 of 24 subjects without clin-
ical evidence of vaccinia virus replication. Vigorous
cytotoxic T-cell and interferon-
 
g
 
 responses occurred
in 94 percent of subjects with vesicles, and a cytotoxic
T-cell response occurred in only one subject without
a vesicle.
 
Conclusions
 
The vaccinia virus vaccine (which was
produced in 1982 or earlier) still has substantial poten-
cy when administered by a bifurcated needle to previ-
ously unvaccinated adults. Diluting the vaccine reduc-
es the rate of successful vaccination. The development
of vesicular skin lesions after vaccination correlates
with the induction of the antibody and T-cell respons-
es that are considered essential for clearing vaccinia
virus infections. (N Engl J Med 2002;346:1275-80.)
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MALLPOX vaccine (vaccinia virus) is highly
effective in immunizing against smallpox and
can prevent disease when given as late as two
to three days after exposure.
 
1
 
 A comprehen-
sive public health program coupled with vaccination
enabled the World Health Assembly to declare the
world free of smallpox in 1980.
 
2
 
 General use of the
vaccine in the United States ended in 1972. Cur-
rently, less than half the world’s population has been
S
 
exposed either to smallpox (variola virus) or to the
vaccine.
 
3
 
 This fact prompted several government and
world health authorities to warn about the serious
threat of smallpox as a biologic weapon.
 
3,4
 
 The prob-
ability of a release of smallpox is not known, but the
effect could be catastrophic in an unimmunized pop-
ulation.
 
5
 
The immune responses required to protect a per-
son from smallpox after vaccination are not com-
pletely understood. Inadvertent vaccination resulted in
severe complications and death from vaccinia in chil-
dren with a T-cell deficiency
 
 
 
and an adult with undi-
agnosed infection with human immunodeficiency
virus type 1 (HIV-1) but not in children with agam-
maglobulinemia.
 
6-8
 
 Therefore, detailed analyses of
T-cell responses in addition to antibody responses af-
ter vaccination may improve our understanding of the
effects of dilution on the immunogenicity of vaccinia
virus vaccine.
The last lots of vaccinia vaccine manufactured in
the United States, in 1982, were produced by the clas-
sic method involving scarification of calves followed by
collection of vaccinia virus from draining calf lymph.
Concern about contamination with bacteria or other
agents from bovines makes further use of this method
unfeasible. The lyophilized vaccine, which is stored at
the Centers for Disease Control and Prevention
(CDC) in Atlanta, contains approximately 10
 
8
 
 pock-
forming units per milliliter. Supplies of lyophilized
vaccine in the United States consist of an estimated
15 million doses. In addition, 70 to 90 million doses
of frozen liquid-formulation smallpox vaccine have
been identified in long-term storage by a vaccine man-
ufacturer (Aventis, Swiftwater, Pa.); the U.S. govern-
ment is reportedly negotiating to acquire this vaccine.
Efforts are under way to develop a tissue-culture–
derived vaccinia virus vaccine.
 
9
 
 In the interim, we
evaluated the available vaccine to determine whether
dilution altered the rate of successful viral replication
at the inoculation site and immune responses.
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METHODS
 
Vaccine
 
The vaccine (Dryvax, Wyeth Laboratories, Marietta, Pa.; lot no.
4998391 [titer, 10
 
7.7
 
 plaque-forming units, or pfu, per milliliter]
and lot no. 4008257 [titer, 10
 
7.8
 
 pfu per milliliter]) and diluent
were provided by the CDC. The vaccine is a lyophilized product
prepared from calf lymph. The diluent contains 50 percent glyc-
erin, 0.25 percent phenol, and 0.005 percent brilliant green dye
in water. The vaccine was reconstituted on the day of administra-
tion according to the package insert. The undiluted vaccine was se-
rially diluted with diluent. Coded vials were stored at 4°C until use.
Because the vaccine was highly viscous and difficult to manipulate,
viral titers were determined in each of the 19 vials prepared, as de-
scribed previously.
 
10
 
 Titers are expressed as the number of plaque-
forming units per milliliter.
 
Study Design and Subjects
 
The study was a randomized, double-blind trial conducted at
the National Institute of Allergy and Infectious Diseases Vaccine
and Treatment Evaluation Unit in St. Louis. The protocol was ap-
proved by the institutional review board of Saint Louis University.
All subjects provided written informed consent and were enrolled
between April 2000 and October 2000. Long-term follow-up to
assess the duration of immune responses is ongoing.
Healthy adults 18 to 30 years of age were eligible if they had no
vaccination scar; no history of vaccinia virus vaccination; normal re-
nal and hepatic serum chemical values; negative tests for hepatitis
B surface antigen, hepatitis C virus antibody, and rapid plasma re-
agin; and a negative HIV-1 enzyme-linked immunosorbent assay
(ELISA). Exclusion criteria included the contraindications against
vaccination noted in the package insert (pregnancy, immunosup-
pression, and eczema), a history of vaccination with live attenu-
ated virus within 60 days before the study, the receipt of blood
products or immune globulin within 6 months before the study,
and household contact, sexual contact, or occupational exposure to
pregnant women, immunosuppressed persons, persons with ecze-
ma, or infants less than 12 months of age.
A total of 60 subjects were enrolled and were randomly as-
signed to receive undiluted vaccine, a 1:10 dilution of vaccine, or
a 1:100 dilution of vaccine. Twenty subjects were enrolled in each
group. Group assignment was revealed to the subjects after day
45. Laboratory personnel remained unaware of treatment assign-
ments until all assays were completed. Subjects were inoculated by
scarification: a bifurcated needle that held a drop of vaccine was
pressed 15 times into the skin of the upper arm. Vaccination sites
were covered with folded gauze and a semipermeable adhesive
membrane (Tegaderm, 3M Health Care, St. Paul, Minn.) to avoid
autoinoculation or exposure of personal contacts. Dressings were
changed every three to five days until the lesion formed an eschar.
The primary end point was the rate of success of vaccination.
Success was defined by the presence of a primary vesicle at the
inoculation site seven to nine days after scarification. Other signs
and symptoms of the replication of vaccinia virus include edema,
tenderness, and erythema at the site of vaccination and regional
lymphadenopathy. Subsequently, the vesicle (Fig. 1) evolves into a
small ulcer over which a scab forms, ultimately leaving a small scar.
The determination of successful vaccination was made by a single
physician who was unaware of the subjects’ treatment assignments.
Secondary end points included measurement of antibody responses
and cellular immune responses.
 
Isolation of Virus and Antibody Assays
 
Swab samples of each lesion were obtained on day 7, 8, or 9 after
scarification and cultured on continuous African-green-monkey
kidney cells (BSC-40 cells), and the virus present in the swab sam-
ples was quantitated by a plaque assay as described previously.
 
10
 
Neutralization assays were performed on serum samples collected
just before vaccination (day 0) and one month and one year after
vaccination; the end point was a 60 percent reduction in the
number of plaques as described previously.
 
11
 
 Serum binding an-
tibody levels were measured by ELISA as described previously.
 
12
 
Vaccinia virus antigen and serum samples to be used as positive
and negative controls were provided by Dr. George Ludwig (U.S.
Army Medical Research Institute of Infectious Diseases, Fort De-
trick, Md.).
 
Cytotoxicity Assays
 
Cryopreserved peripheral-blood mononuclear cells obtained
from all subjects on day 0 and at six months were thawed and test-
ed in the same assay. Target cells were autologous Epstein–Barr vi-
rus–transformed lymphoblastoid cells that had been infected with
vaccinia virus one day earlier and that were labeled with chromi-
um-51 on the day of the assay.
 
13,14 
 
Effector cells were exposed to
virus-infected autologous peripheral-blood mononuclear cells for
six days at 37°C and then added at various effector–target ratios
(10:1, 30:1, and 90:1) in 96-well 
 
U
 
-bottom plates, in triplicate, for
4.5 hours as described previously.
 
14,15 
 
At each effector–target ratio,
vaccinia-specific immune lysis was calculated as the difference be-
tween the percent lysis of infected targets and the percent lysis of
uninfected targets. The number of effector cells required to lyse 30
percent of target cells (referred to as lytic units) per million cells was
determined by an exponential-fit method
 
16
 
 with the use of commer-
cial software (Proteins International, Rochester Hills, Mich.).
 
Interferon-g
 
 Assays
 
A modified enzyme-linked immunospot assay was used to de-
tect live virus-specific release of interferon-
 
g
 
 by cryopreserved pe-
ripheral-blood mononuclear cells as previously described,
 
16
 
 except
that stock vaccinia virus was used to stimulate peripheral-blood
mononuclear cells at a multiplicity of infection of 1.0 pfu per cell.
The frequency of interferon-
 
g
 
–positive T cells specific for vaccin-
ia virus per million peripheral-blood mononuclear cells was de-
termined, and the results were considered positive if the number
of spots per million peripheral-blood mononuclear cells in virus-
stimulated wells was twice as high as the number of spots per mil-
lion cells in the control wells and if at least 20 spots per million
peripheral-blood mononuclear cells were present. Preliminary
studies (Ennis FA: unpublished data) indicated that most of the
T cells that release vaccinia virus–specific interferon-
 
g
 
 are CD8+.
 
Proliferation Assays
 
Proliferation assays were performed in replicates of five as de-
scribed previously.
 
14,15,17
 
 For each group of five replicates, the stim-
ulation index was calculated as the mean of the three intermediate
values (expressed as counts per minute).
 
Statistical Analysis
 
The objective of this study was to assess the effects of diluted
vaccinia virus vaccine on clinical and laboratory indicators of pro-
tective immunity. To be considered successful, a given dilution
had to evoke a response in at least 18 of the 20 subjects in a group
(a success rate of 90 percent). Thus, a sample size of 20 involved
an 8 percent chance of rejecting a vaccine with a 95 percent suc-
cess rate and a 32 percent chance of rejecting a marginally accept-
able vaccine with a 90 percent success rate. A sample size of 20
was selected on the basis of these considerations and the under-
standing that the selection of a dilution will not depend solely on
the dichotomous measure of success or failure in any group. Pairs
of success rates were compared with use of standard asymptotic
methods for binomial comparisons, and all three groups were com-
pared with use of the Kruskal–Wallis test for trend.
 
18
 
T-cell responses were analyzed by analysis of variance with the
use of SPSS statistical software (SPSS, Chicago). Multiple post hoc
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comparisons of the study groups were made with the use of the
Tukey adjustment for multiplicity. All t-tests were two-sided.
 
RESULTS
 
Clinical Findings
 
Of the 60 subjects, 2 had a fever (temperature, up
to 39°C [102.2°F]) for 1 or 2 days beginning 11
and 12 days, respectively, after vaccination. One sub-
ject reported a stiff neck on days 12 and 13 after vac-
cination. One subject reported intermittent dizziness,
floaters, and tachycardia starting on day 15 after vac-
cination and lasting two weeks. One subject had an
intermittent rash on the arms and legs and muscle
aches on days 9 through 13. Two subjects had an el-
evated alanine aminotransferase level («84 U per li-
ter) on day 28; the elevation resolved two weeks later
in one subject and was still present at the time of the
last follow-up visit in the other. One subject had a
transient, mild decrease in the hemoglobin level (13.4
to 11.7 g per deciliter) on day 28. On urinalysis at
six months, one subject transiently had 11 white cells
per high-power field. Three subjects reported that
the skin around the dressing was irritated. One sub-
ject in whom vaccination failed reported myalgias and
pain at the vaccination site seven days after vaccina-
tion. There were no serious adverse events. One
subject who received the 1:100 dilution of vaccine
withdrew after vaccination for reasons unrelated to
the study. Fifty-five of the subjects provided blood
specimens at one year, as planned.
 
Success Rates
 
Vaccination success rates — defined by the forma-
tion of a vesicle at the inoculation site seven to nine
days after vaccination — were dose-dependent (P<
0.001 by the Kruskal–Wallis test): vaccination was
successful in 19 of 20 subjects who received undiluted
vaccine (mean viral titer, 10
 
7.8
 
 pfu per milliliter; range,
10
 
7.4
 
 to 10
 
8.3
 
), 14 of 20 who received a 1:10 dilution
(mean viral titer, 10
 
6.5
 
 pfu per milliliter; range, 10
 
6.1
 
to 10
 
7.0
 
), and 3 of 20 who received a 1:100 dilution
(mean viral titer, 10
 
5.0
 
 pfu per milliliter; range, 10
 
4.2
 
to 10
 
5.9
 
). The success rate was significantly lower in
the group that received the 1:10 dilution than in the
group that received the undiluted vaccine (70 per-
cent vs. 95 percent; absolute difference, 25 percent;
95 percent confidence interval for the difference, 3 to
47 percent; P=0.03 with the use of asymptotic
methods). Once viral infection of the skin was initi-
ated, the resulting lesion was approximately 1 cm in
diameter, regardless of the dose of vaccine. Vaccinia
virus was isolated from swab samples of skin lesions
in 35 of the 36 subjects with vesicles.
 
Figure 1.
 
 Typical Vesicle on the Upper Arm 10 Days after Scarification.
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Antibody Responses
 
Among 36 subjects with vesicles, neutralizing an-
tibody titers and antibody titers on ELISA increased
by a factor of at least 4 at one month in 34 and 26
subjects, respectively (Table 1). In the 33 subjects with
vesicles who returned for follow-up at one year, neu-
tralization titers at one year averaged 23.7 percent of
the titers on day 28 (95 percent confidence interval,
7 to 33 percent) and ELISA titers averaged 64.3
percent of the titers on day 28 (95 percent confi-
dence interval, 44.8 to 96.6 percent) (Table 1).
 
Cytotoxic T-Cell and Interferon-g
 
 Responses
 
The development of a vesicle correlated with the
development of cytotoxic T-cell responses in 31 of
32 subjects (of 4 other subjects with vesicles, 2 had
nonviable cells and 2 had a high background response
on the cytotoxic T-cell assay) and an increase in the
number of T cells positive for virus-specific interfer-
on-
 
g
 
 by enzyme-linked immunospot assay in 31 of
34 subjects. Figure 2A demonstrates vaccinia virus–
specific cytotoxic T-cell activity six months after scar-
ification with undiluted vaccine, the 1:10 dilution of
vaccine, and the 1:100 dilution of vaccine. When the
magnitude of the cytotoxic T-cell responses was based
on the percent lysis among subjects with vesicle for-
mation in each group, there was no significant dif-
ference between the group given undiluted vaccine
and the group given the 1:10 dilution (P=0.052),
but the difference between the group given undiluted
vaccine and the group given the 1:100 dilution was
significant (P<0.001). None of the subjects had vac-
cinia virus–specific cytotoxic T-cell activity on day 0
(before vaccination). One subject in the group given
the 1:100 dilution did not have a vaccinial skin lesion
but did have a virus-specific cytotoxic T-cell response
after vaccination (Fig. 2A). 
Enzyme-linked immunospot assays were used to
determine the number of cells that produced vaccinia
virus–specific interferon-
 
g
 
 in peripheral-blood mono-
nuclear cells obtained before and six months after vac-
cination. As shown in Figure 2B, the numbers were
significantly different among the three groups. The
presence of cells producing vaccinia virus–specific in-
terferon-
 
g
 
 correlated with the development of both a
vesicle and a cytotoxic T-cell response. One subject
who received the 1:100 dilution had a positive en-
zyme-linked immunospot assay and a cytotoxic T-cell
response but did not have a skin response to the vac-
cine. Three subjects with vesicle formation did not
have a positive enzyme-linked immunospot assay. In
subjects with vesicle formation, the magnitude of the
interferon-
 
g
 
 response was significantly lower among
those given the 1:10 dilution of vaccine or the 1:100
dilution than among those given the undiluted vac-
cine (P=0.038 and P<0.001, respectively). 
 
Lymphocyte Proliferation
 
Lymphocyte proliferation was induced in response
to vaccinia virus in 33 of 34 subjects with vesicle for-
mation and in none of 23 subjects without vesicle
formation (Fig. 2C). There were no significant dose-
related differences in the stimulation index at six
months among subjects with vesicle formation, al-
 
*Clinical success was defined by the formation of a vesicle at the inoculation site seven to nine days after vaccination.
The titer in each group is the mean value for 19 vials. Values shown for the geometric mean titer (GMT) after vaccination
are the mean titers in subjects who had vesicles. ELISA denotes enzyme-linked immunosorbent assay.
†Data shown are for subjects with vesicles.
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OT
 
 P
 
REVIOUSLY
 
 BEEN VACCINATED.*
VARIABLE
UNDILUTED VACCINE
(DOSE, 107.8 pfu/ml)
1:10 DILUTION
(DOSE, 106.5 pfu/ml)
1:100 DILUTION
(DOSE, 105.0 pfu/ml)
Clinical success — no. of subjects/total no. (%)
Mean maximal size of resulting lesion — mm
19/20 (95)
11.6
14/20 (70)
10.6
3/20 (15)
10.3
Serum neutralizing antibody titer
Increase by a factor of 4 or more at 1 mo
— no. of subjects/total no.†
Measurable titer at 1 yr — no. of subjects/no. tested
Reciprocal GMT at 1 mo
Reciprocal GMT at 1 yr
17/19
15/17
36
11
14/14
9/13
41
6
3/3
3/3
25
10
Serum antibody titer on ELISA
Increase by a factor of 4 or more at 1 mo
— no. of subjects/total no.†
Measurable titer at 1 yr — no. of subjects/no. tested
Reciprocal GMT at 1 mo
Reciprocal GMT at 1 yr
14/19
17/17
430
245
11/14
10/13
328
170
2/3
3/3
400
159
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though there were significant overall dose–response
differences in the stimulation index between the group
given undiluted vaccine and the group given the 1:100
dilution (P=0.039), because of the higher frequen-
cy of nonresponse in the latter group. Examination of
peripheral-blood mononuclear cells obtained before
vaccination indicated that none of the subjects had
had previous exposure to the virus (data not shown).
DISCUSSION
Immunization with vaccinia virus remains the
only available option for protection against smallpox
infection. The current supply of vaccine is viable and
has a good titer, but dilution of the vaccine to titers
of less than 107 pfu per milliliter reduced the rates of
successful vaccination. Serial dilution of the vaccine
stock resulted in nonlinear reductions in the titer
(e.g., a 1:100 dilution reduced the titer from 107.8
pfu per milliliter to 105.0 pfu per milliliter). This ef-
fect may result from the highly viscous nature of the
preparation. As compared with the 95 percent rate
of success associated with the undiluted vaccine, the
rate of success associated with the dose of 106.5 pfu
per milliliter provided by the 1:10 dilution was 70
percent. This lower rate is similar to the 75 percent
rate reported among children who were vaccinated
with a similar vaccine and dose (107 pock-forming
units per milliliter).19 The dose of 105.0 pfu per mil-
liliter provided by the 1:100 dilution was associated
with a success rate of only 15 percent. These results
indicate that serial dilution of the current vaccine to
less than 106.5 pfu per milliliter results in a loss of po-
tency (P=0.001 for the comparison of undiluted
vaccine with a 1:10 dilution alone and P<0.001 for
the comparison of undiluted vaccine with both di-
lutions of vaccine).
There was a dose–response effect: higher doses
produced significantly stronger cytotoxic T-cell and
interferon-g responses. Given the small number of
subjects in whom vaccination with a 1:10 or 1:100
dilution was successful, additional study is needed to
confirm these observations. Findings in vaccinated
children and adults with T-cell–related immunode-
ficiencies indicate that T-cell responses are a critical
element in the recovery from pox virus infections.6-8
The cytotoxic T-cell and interferon-g responses in our
study were much stronger than those reported after
the receipt of experimental HIV-1 vaccines and cor-
Figure 2. T-Cell Responses to Vaccinia Virus Six Months after Vaccination with Undiluted Vaccine, a 1:10 Dilution of Vaccine, or a
1:100 Dilution of Vaccine, According to the Presence or Absence of Vesicle Formation at the Inoculation Site within Seven to Nine
Days after Vaccination.
Panel A shows the cytotoxic T-cell responses. The actual values for two outliers are shown. Panel B shows the number of cells
producing vaccinia virus–specific interferon-g. Panel C shows the degree of lymphocyte proliferation in response to vaccination.
Two subjects with vesicles, one each from the group given undiluted vaccine and the group given the 1:10 dilution, had nonviable
peripheral-blood mononuclear cells (PBMC) and could not be tested in any of the cell-mediated immune assays, and one subject
in the group given the 1:100 dilution who did not have vesicle formation did not have blood drawn. One subject each in the group
given undiluted vaccine and the group given the 1:10 dilution who had vesicle formation had high background values in the cyto-
toxic T-cell assay, which prevented interpretation of the results (Panel A). The stimulation index is the mean of the three interme-
diate values in each replicate of five. Higher values indicate greater proliferation of lymphocytes. The number in parentheses indi-
cates the number of subjects with a stimulation index of 1, all of whom received the 1:100 dilution. Dashed lines in Panels B and C
indicate the cutoff values for a positive response. 
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respond to the levels of memory T cells specific for
measles virus in adults16 and to the strength of cyto-
toxic T-cell responses recorded in adults after the re-
ceipt of yellow fever vaccine.20 In addition, almost all
subjects with vesicle formation had strong vaccinia
virus–specific cytotoxic T-cell responses as well as in-
creased numbers of interferon-g–producing T cells.
These findings suggest that, regardless of the dose of
vaccine, if a vesicle forms, the resulting brisk T-cell
and humoral responses will be protective.
Diluting the available vaccine to titers of 106.5 pfu
per milliliter or less reduced the frequency rates of
local viral replication and vesicle formation — effects
that are essential stimuli for protective immune re-
sponses, as evidenced by the lack of antibody, cyto-
toxic T-cell, and interferon-g responses. Previous re-
ports in which smallpox vaccination in patients with
defects in either cellular or humoral immunity led to
severe vaccinia underscore the essential role of T-cell
responses and antibody in protecting against pox vi-
ruses, such as variola.21 In our study, the induction
of vaccinia virus–specific T-cell and B-cell responses
was associated with clinically observable pox lesions.
Previous studies have shown that the response is at-
tenuated if the route of administration differs from
the one that we used.19,22 We found that the absence
of primary skin vesicles after the administration of
diluted vaccine was associated with the absence of
vaccinia virus–specific T-cell or B-cell responses and
is therefore likely to indicate the absence of protective
immunity. Future studies are needed to assess the ef-
fectiveness of vaccine titers of 106.5 to 108.0 pfu per
milliliter in both previously vaccinated and unvacci-
nated populations. Evaluation of new cell-culture–
derived vaccines should address both T-cell and B-cell
responses. If vaccinations with dilutions of the cur-
rent vaccine are administered, revaccination should be
considered in persons without vesicle formation.
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